• If you are wondering whether DaVita's current share price reflects its true worth, this breakdown will help you connect the recent moves in the stock with what the underlying valuation signals are saying.
• DaVita last closed at US$155.03, with returns of 4.7% over the past week, 1.1% over the past month, 35.4% year to date, 11.1% over 1 year, 76.2% over 3 years and 35.4% over 5 years.
• Recent coverage around DaVita has focused on how the stock fits within the broader healthcare space and how its current pricing compares with peers and market expectations. This context helps explain why some investors are rethinking both the potential upside and the level of risk they are comfortable taking on with the shares.
• DaVita currently records a valuation score of 5 out of 6. The sections that follow will walk through the standard valuation checks used to arrive at this score, and then finish with a way to look beyond the numbers to understand what that valuation really means for you.

Approach 1: DaVita Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting future cash flows and discounting them back to today using an appropriate rate. It is essentially asking what all of DaVita’s future cash flows are worth in today’s dollars.

For DaVita, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is $1,285.87 million. Analysts provide a Free Cash Flow estimate of $1,244 million for 2026, and Simply Wall St then extends this with further projections out to 2035. Those extended projections range from $1,230.19 million to $1,459.92 million, with each future figure discounted back to today.

Adding up those discounted cash flows gives an estimated intrinsic value of about $389.70 per share. Compared with the recent share price of $155.03, the DCF output implies a 60.2% discount. This indicates that the shares may be trading well below this cash flow based estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests DaVita is undervalued by 60.2%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: DaVita Price vs Earnings

P/E is a common way to look at profitable companies because it links what you pay directly to the earnings each share generates. For any stock, a higher P/E usually reflects higher growth expectations or lower perceived risk, while a lower P/E tends to be associated with more modest prospects or higher uncertainty.

DaVita currently trades on a P/E of 14.2x. That sits well below the Healthcare industry average of about 24.1x and also below the peer group average of 39.2x. On simple comparisons, the shares look inexpensive relative to both the sector and similar companies.

Simply Wall St’s Fair Ratio for DaVita is 23.1x. This is a proprietary estimate of what a more “normal” P/E might look like after factoring in items such as the company’s earnings profile, industry, profit margins, market capitalization and key risks. That makes it more tailored than a blunt comparison to peers or the overall industry, which can be skewed by companies with very different growth outlooks or risk levels. With DaVita trading at 14.2x versus a Fair Ratio of 23.1x, the shares screen as undervalued on this P/E based view.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your DaVita Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and on Simply Wall St this comes through Narratives. These let you attach a clear story about DaVita to hard numbers by linking your view on its future revenue, earnings and margins to a forecast and a fair value. You can then compare that fair value with the current price to help you decide when to act. All of this happens within the Community page, where Narratives are updated as new news or earnings arrive. A more bullish DaVita Narrative might lean toward the higher analyst fair value near US$179.66, while a more cautious Narrative could sit closer to US$126, reflecting different assumptions about long term treatment volumes, margins, buybacks and discount rates.

For DaVita, however, we will make it really easy for you with previews of two leading DaVita Narratives:

Fair value: US$179.66

Implied undervaluation versus the recent US$155.03 price: 13.7%

Analyst revenue growth assumption: 4.8% a year

• Focuses on technology and AI investments, Integrated Kidney Care and payer mix optimization as key drivers for higher margins and free cash flow over time.
• Builds on bullish analyst assumptions for revenue, earnings, margins and ongoing share repurchases, all discounted at 8.1% to reach an optimistic fair value.
• Highlights risks such as policy changes, persistent cost pressures and slower than expected benefits from technology spend that could challenge the upbeat case.

Fair value: US$151.71

Implied overvaluation versus the recent US$155.03 price: 2.2%

Analyst revenue growth assumption: 3.6% a year

• Anchors on the analyst consensus view, where current pricing sits close to fair value and future returns depend heavily on execution and buyback pace.
• Assumes more moderate improvements in margins and earnings, with share count reduction and a lower future P/E doing much of the work in the model.
• Flags persistent mortality, reimbursement headwinds, slower clinical adoption and softer ancillary revenues as ongoing constraints on growth, margins and cash flow.

Do you think there's more to the story for DaVita? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.